Palonosetron (Palonosetron Hydrochloride)

Palonosetron, the active ingredient in this product, is a 5-HT3 receptor antagonist presented as an intravenous solution for IV use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to specific therapeutic pathways.

- Chemotherapy‑induced nausea and vomiting (CINV): Provides prophylaxis of acute and delayed CINV in adult patients receiving highly or moderately emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgical procedures requiring general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps mitigate the nausea and vomiting associated with radiation treatment of the abdomen or pelvis. - Anticipatory nausea and vomiting: Decreases the psychological anticipatory response in patients with a history of CINV. - Nausea related to other emetogenic triggers such as opioid‑cann c ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  ​  ​  ​  ​  

Palonosetron      …  …  …  ...

Palonosetiv